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Abstract: 28 
A significant problem affecting gene therapy approaches aiming at achieving long-term 29 
transgene expression is the immune response against the protein product of the 30 
therapeutic gene, which can reduce or eliminate the therapeutic effect. The problem is 31 
further exacerbated when therapy involves targeting an immunogenic tissue and/or one 32 
with a pre-existing inflammatory phenotype, such as dystrophic muscles. In this proof-of-33 
principle study we co-expressed a model antigen, bacterial β-galactosidase, with an 34 
immunosuppressive factor, indoleamine 2,3-dioxygenase 1 (IDO1), in muscles of the mdx 35 
mouse model of Duchenne muscular dystrophy. This treatment prevented loss of 36 
expression of the transgene concomitant with significantly elevated expression of T 37 
regulatory (Treg) markers in the IDO1-expressing muscles. Moreover, co-expression of 38 
IDO1 resulted in reduced serum levels of anti-β-gal antibodies. These data indicate that 39 
co-expression of genes encoding immunomodulatory enzymes controlling kynurenine 40 
pathways provide a viable strategy for preventing loss of transgenes targeted into 41 
dystrophic muscles with pre-existing inflammation. 42 
 43 
Introduction 44 
A common problem in the development of gene therapy for inherited deficits is the risk of 45 
immune responses against the re-expressed therapeutic protein. Such protein, due to the total 46 
absence of its endogenous expression or because of differences with the endogenous mutant 47 
gene product, becomes a neo-antigen. The transgene-expressing cells also become the immune 48 
response target, which leads to the cessation of the therapeutic effect and often to further tissue 49 
damage (1, 2). The consequences to the recipient can range from transient without significant 50 
impairments to severe and life threatening. Many factors affect the immunogenicity of 51 
therapeutic proteins. Some of these are protein-related, e.g. dose and antigenicity. Others are 52 
disease/tissue - related, e.g. the underlying immune status and the target tissue promoting 53 
immune responses. Skeletal muscle is an immunogenic location (3) and muscle diseases are 54 
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often associated with chronic sterile inflammation, which exacerbates the highly unfavorable 55 
environment. 56 
Duchenne muscular dystrophy (DMD) is an inherited muscle-wasting disease (4) with 57 
inflammation (5) leading to severe disability and death of young men. Currently, no treatment 58 
improves the long-term outcome. Unfortunately, there is evidence that immunogenic epitopes 59 
resulting from new therapeutic modalities aiming at restoration of dystrophin expression (6-9) 60 
can result in treatment failure in both experimental and clinical trials (10). Therefore, 61 
prevention/suppression of immune responses is pre-requisite for successful therapies. While 62 
broad immunosuppression has been shown to prolong transgene expression (11, 12), it 63 
disrupts immune responses against pathogens, which is not without risks in already heavily 64 
handicapped patients. In contrast, development of methods to induce tolerance to a therapeutic 65 
protein would provide a significant advancement in gene therapy.  66 
 67 
While expression of protein in a naïve organism usually causes immunisation, it may also lead to 68 
the development of the immune tolerance. Mechanisms causing the switch between T cell 69 
response and unresponsiveness include T cell anergy, clonal deletion of antigen-specific T 70 
lymphocytes and regulatory T cell (Treg) activation (13).  Whether a T cell becomes an effector 71 
cell or is tolerised depends on the status of antigen-presenting cells (APCs) that interact with it 72 
(14-18). This activation status of APCs is, in turn, dependent on the inflammatory signals 73 
provided by tissue damage, cytokine content, gene therapy vector and inflammatory signals. 74 
The catabolism of the essential amino acid L-tryptophan by indoleamine 2,3-dioxygenase (IDO) 75 
and tryptophan 2,3-dioxygenase (TDO) enzymes produces kynurenines, which regulate innate 76 
and adaptive immune system and maintain tolerance to “self” antigens (19). IDO1 plays a key 77 
role in fetal-maternal tolerance, and animals exposed to antigen neonatally were found unable 78 
to mount humoral or cytotoxic responses when re-challenged with DNA constructs encoding 79 
such antigens as adults (20-23). Importantly, there is evidence that IDO1 induces peripheral 80 
tolerance and the retro-control of immune responses (24). 81 
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We provide a proof-of-principle that an approach co-triggering the kynurenine mechanism 82 
prolongs expression of a model antigenic transgene in adult dystrophic mdx mouse muscles. 83 
Importantly, the IDO does not need to be targeted to specific cells. 84 
 85 
Results & Discussion 86 
To minimise the confounding immunizing and immunomodulatory effects of viral vector 87 
proteins we used intramuscular targeting of plasmid vectors expressing bacterial β-88 
galactosidase (lacZ gene) model antigen alone or co-expressed with mouse IDO1. 89 
Engineering, expression and characterisation of vectors 90 
The choice of the promoter/enhancer elements controlling the transgene can seriously affect its 91 
immunogenicity. The ubiquitously-active control elements (e.g. CMV) trigger immune responses 92 
because transgenes become expressed directly in the APCs, which results in increased antigen 93 
presentation (25) and rapid recruitment of cytotoxic T cells (CTLs). Tissue-specific 94 
promoter/enhancer control can improve the duration of transgene expression.  Nevertheless, 95 
for many transgenes, immune responses (albeit humoral, of lower magnitude and delayed in 96 
comparison with the CMV-driven construct) are still being triggered because proteins released 97 
from cells are processed and presented by APCs, which causes activation of T-helper cells and 98 
ultimately the response. Therefore, to maximise the immunogenic effect, we used the CMV 99 
promoter. For tolerance induction we generated two mouse IDO1-expressing plasmids: 100 
pcDNA3.CMV.mIDO1 driven by the same ubiquitously-active CMV and pcDNA3.CD11c.mIDO1 101 
controlled by the minimal CD11c promoter shown previously to be active primarily in dendritic 102 
cells and macrophages (25-27). The pcDNA3.CD11c.mIDO1 was made by excision of the CMV 103 
promoter using MfeI and Acc65I and ligation of the fragment containing the 760 bp mouse 104 
CD11c minimal promoter region. The expression of IDO1 from these constructs was assessed 105 
following transfection of SC5 dystrophic myoblasts (28), HEK-293 cells or RAW264.7 mouse 106 
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macrophages in vitro and Western blotting confirmed IDO1 protein being expressed in 107 
transfected HEK293 cells (Fig 1A). The same approach was used to confirm expression of the 108 
pcS2+β-gal plasmid (Fig 1B). 109 
 110 
Co-administration of IDO1 plasmid reduces loss of β-gal expression in skeletal muscles in vivo. 111 
We targeted β-gal into Tibialis anterior muscles of 4 week old male mdx mice as, at this stage, 112 
the mdx muscle has all the hallmarks of the disease with its highly inflammatory environment. 113 
β-gal expression was initially analysed 7, 14 and 21 days following a single i.m. plasmid 114 
injection. This time-course analysis revealed that β-gal was readily detectable in injected 115 
muscles at 7 days. Protein expression was decreased at 14 and undetectable at 21 days (Fig 2A). 116 
Subsequently, this plasmid dose was injected alone (control) or co-injected with one of the 117 
IDO1-expressing plasmids and β-gal expression was analysed at 14 days (Fig 2B-2D). 118 
Western blotting analysis of muscle extracts revealed that only 25% of muscles injected with 119 
the lacZ plasmid alone had detectable β-gal protein expression 14 days post-injection. In 120 
contrast, 69% of muscles co-injected with pcDNA3.CMV.mIDO1 plasmids showed detectable β-121 
gal expression while co-injection with pcDNA3.CD11c.mIDO1 plasmid (targeting IDO1 to APCs) 122 
resulted in protein being expressed in 42% of muscles (Fig 2B). Therefore, IDO1 does not need 123 
targeting to APCs. At the equal dose, the qPCR analysis (Fig 2C) demonstrated that the 124 
individual expressions of the lacZ transcript relative to GAPDH endogenous control were higher 125 
in the majority of co-injected samples but the averages did not differ significantly due to highly 126 
variable expression levels and the relatively low sample number. However, injection of double 127 
the amount of β-gal plasmid in the control group resulted in statistically significant reduction 128 
rather than increase of this protein expression, thus confirming that higher β-gal expression in 129 
co-injected muscles was due to the IDO1 immunosuppression (Fig 2D). The lacZ expression 130 
heterogeneity was confirmed in the muscle sections stained with X-gal: Some of the fibres were 131 
strongly labelled while others were expressing very low transgene levels (Fig 3). This was in 132 
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agreement with previous studies using injection of naked lacZ plasmids into skeletal muscles 133 
(29).  134 
IDO1 expression changes the inflammatory profile in injected muscles 135 
Analysis of serial transverse sections of TA muscles showed inflammatory cells to be 136 
surrounding and infiltrating both the highly- and the weakly-expressing fibres (Fig 3). There 137 
was no significant difference between samples injected with β-gal or co-injected with IDO1 138 
plasmids. The immunohistochemical analysis of markers for the specific inflammatory cell 139 
subpopulations infiltrating the tolerised vs. non-tolerised muscles was inconclusive (data not 140 
shown).  141 
To distinguish the exogenous from the endogenous IDO1 expression we used RT-PCR with 142 
primers detecting the plasmid-driven transcript only (Fig 4A). Having confirmed the exogenous 143 
IDO1 expression, qPCR was used to establish the relative levels of IDO1 mRNA and that 144 
confirmed a statistically-significant increase in the co-injected muscles (Fig 4B).  145 
The qPCR analysis of several key marker genes for different T cell subsets showed statistically 146 
significant increase in the expression of Cd4, Cd8 and forkhead box P3 (Foxp3) genes in muscles 147 
co-injected with IDO1 plasmids (Fig 5). This pattern is interesting as increased expressions of 148 
lymphocyte markers were concomitant with higher levels of Foxp3. This transcription factor 149 
regulates the development and function of T-regulatory (T-reg) cells (30) and therefore 150 
overexpression of IDO1 appears to prolong antigen expression via the induction of T-regs.  151 
The levels of interleukin 10 (Il10) and Il12a expression did not show statistically significant 152 
differences in these samples (Fig 5). Previous studies demonstrated regulatory interactions 153 
between IDO1, IL-10 and IL-12 in antigen presenting cells (31, 32) and IDO1 suppresses the IL-154 
10, as kynurenic acid reduces IL-10 production (33). Interestingly, the decrease in expression of 155 
IL-10, which is an anti-inflammatory cytokine (34, 35) and one of the mediators of T-reg 156 
functions, did not reach statistical significance in IDO-1-expressing muscles. Similarly IL-12, 157 
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which is involved in the development of Th1 CD4+ T cells, which leads to cytotoxic T-lymphocyte 158 
activation (36) and also activate natural killer (NK) cells (37) was not significantly reduced, 159 
although its levels were consistently lower in IDO1-injected muscles. Therefore, the IL-10/IL-12 160 
regulatory interplay may still have a role in the local microenvironment but changes may not be 161 
detected when analysed globally in an otherwise inflammatory environment of the dystrophic 162 
muscle.  163 
 164 
Finally, the ELISA performed to quantify the serum anti-β-gal antibody levels showed 165 
significantly lower response in animals co-administered with the IDO1 plasmid (Fig 6). This is 166 
consistent with the studies in haemophilic mouse models, which revealed that kynurenins 167 
prevented generation of anti-FVIII antibodies and suppressed FVIII-specific B cells by a 168 
mechanism involving the IDO1-dependent induction of T-regs (38). Interestingly, a recent study 169 
demonstrated a novel role for IDO1, intrinsic to B cells, where it acts as a regulator of humoral 170 
immunity (39). Together, these and our findings indicate that IDO1 strategies for preventing 171 
immunisation in gene therapy approaches should be explored while further studies are needed 172 
to help our understanding of the exact mechanism(s) involved.  173 
In summary, this proof-of-principle study was performed to demonstrate that local expression 174 
of even strong non-self antigens in tissues with pre-existing inflammation can be prolonged 175 
using enzymes modulating kynurenine pathways. These data point towards a viable strategy for 176 
preventing transgene loss in various gene therapy settings. Recently, this approach was used to 177 
induce tolerance to transplanted organs, thus reducing need for immunosuppressive treatments 178 
(40). 179 
 180 
Materials and Methods 181 
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The mdx C57Bl/10ScSn-Dmdmdx/J 4 week old male mice were used in accordance with the 182 
institutional Ethical Review Board and the Home Office (70/7549) approvals.  183 
The lacZ (pcS2+Cβ-gal) and the primary pcDNA3.IDO1 plasmids were obtained via collaboration 184 
(see Acknowledgements).  185 
The following antibodies were used: anti-βgal (ThermoFisher Scientific, A11132), anti-IDO 186 
clone 10.1 (Merck Millipore; 05-840), anti-actin (A2066) and anti-GAPDH (G9545, both Sigma).  187 
 188 
RT-PCR and qPCR analyses 189 
Total RNA was extracted using RNeasy kit (Qiagen) as per manufacturer’s instructions. 1 μg of 190 
RNA was used for cDNA synthesis and 100 ng of cDNA in RT-PCR. Identification of the 191 
exogenous (plasmid-driven)IDO1 was performed using primers: Fv 5’- 192 
GAGGCTGGCAAAGATCTCCTGC -3’ and Rv 5’- GCTCGAGCGGCCGCCTA-3’ in 35 cycles: 94°C; 60°C, 193 
72°C for 1 minute each, followed by a final 9 min elongation step at 72°C.  194 
Quantitative PCR analyses of Cd4, Cd8, Foxp3, Il10 and Il12 transcripts were performed  using 195 
25-50 ng of cDNA with Taqman probes (Applied Biosystems) and ViiA™ 7 Real-Time PCR 196 
System (Life Technology, UK).  All individual muscles were analysed in triplicate and all samples 197 
run on the same plate to avoid inter-run variation. Gapdh was previously determined to be the 198 
most stably expressed gene in dystrophic muscles (41) and thus used as reference to establish 199 
individual gene expression values (2-ΔΔCT).  200 
Construction of cd11c.IDO1 expression vector 201 
The minimal functional region of the 5.3 kb CD11c promoter (25, 26) was amplified from the 202 
pBluescript.CD11c.Beta Globin Ova I plasmid (gift from Dr. Thomas Brocker) using adapter 203 
primers Fv 5’- TCAACGCGTCAATTGAGTATTCTCTTGACCTTGGCTGCC -3’ and Rv 5’ - 204 
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TGAGGTACCGACTGGAGAACAGAAGCAGGC- 3’ with MfeI and Acc65I restriction sites for 35 205 
cycles ( 94°C, 67°C and 72°C for 1 minute each) followed by the final elongation step at 72°C.  206 
The 760 bp amplicon was isolated from an agarose gel, purified and cloned into 207 
pcDNA3.CMV.mIDO1 digested with MfeI and Acc65I that removed the CMV promoter cassette, 208 
resulting in the pcDNA3. CD11c.mIDO1 plasmid. Positive clones were verified by DNA 209 
sequencing. High-purity, endotoxin-free plasmids were made using Endofree Mega Kit (Qiagen, 210 
UK). 211 
In vitro cell transfection  212 
HEK-293 and SC5 myoblast cells were authenticated (Promega, and PowerPlex® 16 HS and 213 
MycoAlert™ PLUS Mycoplasma Detection Kit, Lonza) and cultured as previously described (28). 214 
24h before transfection 250,000 cells were plated in 35 mm dishes. 2 µg of endotoxin-free 215 
plasmid was diluted in Knockout-DMEM (Thermofisher, UK) and complexed with 216 
Lipofectamine, GeneCellin (BiocellChallenge),  FuGene HD (Promega, UK) and K2 (Biontex) at 217 
37°C for 15 min. The transfection reagents were dispersed and cells grown for 24h, transfection 218 
mixtures replaced with the complete medium: Knockout-DMEM with serum (Thermofisher) and 219 
total proteins extracted after 72 h. 220 
Analysis of transgene expression in vivo 221 
Plasmids were diluted in 0.9 % saline. For the co-injection experiments, the lacZ plasmid was 222 
mixed 1:1 (molar ratio) with either pcDNA3.CMV.mIDO1 or pcDNA3.CD11c.mIDO1. 223 
Anaesthetized mdx mice were allocated randomly to the experimental and control groups and 224 
injected aseptically into both Tibialis anterior muscles with 25 µl/muscle (1µg/µl) using the 225 
27G1/2 needle fitted with a plastic collar to maintain depth of injection constant (42). At 226 
specific times post-injection mice were killed by CO2 inhalation and muscles flash-frozen in 227 
liquid nitrogen. Blood was collected and serum prepared using a standard method (41).  228 
Protein extraction 229 
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Frozen TA muscles were crushed in liquid nitrogen and tissue powders re-suspended in 200 μl 230 
ice-cold extraction buffer [1 x cOmplete Lysis M (Roche), 1x cOmplete ULTRA Mini EDTA-free 231 
protease inhibitor cocktail tablet, 1 x PhosSTOP phosphatase inhibitor cocktail tablets (Roche)]. 232 
Samples incubated on ice for 30 min with occasional vortexing were homogenised further by 233 
passing through 27½G needle (3X), centrifuged at 16,000 g for 5 min and protein 234 
concentrations in supernatants measured using the Bicinchoninic acid kit (Sigma, UK). 235 
Western Blotting 236 
 237 
Protein (40-60 μg) was resolved on SDS-PAGE gel and blotted onto Hybond-P membranes (GE 238 
Healthcare). Blots were blocked in 5% w/v non-fat milk in TBST for 1 h prior to probing with a 239 
primary antibody (overnight at 4°C), washed with TBST (10 min, 3X) and incubated with the 240 
appropriate HRP-conjugated secondary antibody for 1 h at RT. Specific protein bands were 241 
visualized using Luminata Forte or Crescendo chemiluminescent substrates (Merck Millipore), 242 
images obtained using G-Box (Syngene). Densitometric analyses of protein bands were made 243 
using exposure times within the linear range and the integrated density measurement function 244 
of Fiji software (43).  245 
 246 
Histological muscle analyses 247 
5-10 μm thick muscle cryosections were fixed in 4% w/v paraformaldehyde solution, washed in  248 
PBS and stained for 3 days at 37°C in PBS with 500 µg/ml X-gal (Promega), 5mM Potassium 249 
Ferricyanide (III), 5mM Potassium Hexacyano Ferrate (II), 2mM Magnesium chloride (all Sigma) 250 
and 0.02% Nonidet P40 (Calbiochem). Sections were washed with TBST, counterstained with 251 
H&E and images captured using Axiophot (Zeiss) microscope. 252 
ELISA 253 
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Serum antibody levels were measured as described previously (1, 44). 96 well Maxisorp® 254 
plates (Nunc) were coated with 100 µl/well βgal (Roche) at 10 µg/ml in bicarbonate buffer (pH 255 
9.6) overnight at 4°C, washed with TBST and incubated at RT for 1h with 200 µl/well of 256 
blocking buffer (2% Tween 20 in PBS without Ca2+/Mg2+). 100 µl/well of serum (1:100-1:5000 257 
in PBS, 2% Tween 20; analysed in triplicate) or, for standard curve, mouse anti-βgal antibody 258 
(1:200-1:40,000; Sigma) were incubated at RT for 2 h. After washing, samples were incubated 259 
with goat anti-mouse HRP antibody (1:5000; Sigma) for 2 h at RT in the dark, washed and 260 
incubated with TMB substrate (BD Biosciences) at 37°C for ~10 min. The reaction was stopped 261 
with 2M H2SO4 and read at 450/550nm in a plate reader (Dynex MRX TC II) against the standard 262 
curve.  263 
Statistical analysis of the data 264 
All experiments were repeated at least 3 times. The data are presented as means ± SEM. All 265 
results were analysed using student T-test or ANOVA with Tukey’s Multiple Comparison post-266 
hoc test and P<0.05 was considered as statistically significant.  267 
 268 
Figure legends 269 
Figure 1 270 
Characterisation of expression vectors in vitro. (A) Representative western blots showing a 271 
42kDa IDO1 band in transfected cells.  1 and 2 denote expression in dystrophic SC5 myoblast 272 
transfected with Lipofectamine or GeneCellin.  Positive control (PC) denotes protein from HEK-273 
293 cells transfected with plasmids driven by the CMV promoter (B) Western blot showing a 274 
120kDa band of β-gal expressed in HEK-293 cells (PC) and in myoblasts (1-4) transfected with 275 
different reagents (1 and 2: GeneCellin, 3: K2, 4: FuGene HD). LC denotes the protein loading 276 
control and B a blank lane. 277 
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Figure 2 278 
Continued muscle expression of β-gal following co-injection with IDO1. (A) Kinetics of β-gal 279 
expression in mdx mouse muscles in vivo: Protein levels were analysed by Western blotting 7, 280 
14 and 21 days post-injection into Tibialis anterior muscles. There was a complete lack of β-gal 281 
expression at 21 days. PC represents the positive control using protein expressed in HEK-293 282 
cells and LC is the protein loading control. (B) Graph representing the numbers of β-gal positive 283 
TA muscles 14 days post-injection, as assessed by Western blotting, demonstrating the 284 
significantly increased numbers of expressing muscles that were co-injected with CD11c-IDO1 285 
plasmid [5 out of 12 muscles (41.67%)] and greater still for CMV-driven IDO1 plasmid [11 out 286 
of 16 muscles (68.75%)] compared to only 4 out of 16 muscles (25%) in the control group. (C) 287 
qPCR analysis: Individual values plot of the relative expression levels (2-ΔΔCT) of β-gal in muscles 288 
14 days post-injection of plasmids (n=5, P=0.068).  (D) β-gal protein levels in Western blots 289 
comparing double the amount of plasmid in the control (BG) group (n=14, **P=0.008).  290 
Figure 3 291 
Heterogeneity of β-gal expression in injected muscles.  (A) X-gal staining shows highly variable 292 
protein expression in a small number of fibres (arrows) per area, with no clear correlation 293 
between inflammatory cell numbers infiltrating positive fibres in muscles injected with lacZ 294 
plasmid only (A,C,D) or co-injected with IDO1 (B,E,). Scale bars = 70 μm. 295 
Figure 4 296 
Expression of exogenous IDO1. (A) Agarose gel electrophoresis of exogenous IDO1 amplification 297 
products. The expected 400 bp band is found in RNA samples from co-injected muscles (1-6) 298 
but not in the muscle sample injected with lacZ only (β-gal) or in the negative control (nc). NEB 299 
quick load 100 bp DNA ladder was used.  (B) Individual values plot of the qPCR analysis 300 
showing significantly higher expression levels (2-ΔΔCT) of IDO1 transcript in co-injected muscles 301 
(BG+IDO1) n=5, **P=0.003.  302 
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Figure 5 303 
Inflammatory gene expression changes in IDO1 co-injected muscles. Individual values plot of 304 
the relative expression levels (2-ΔΔCT) demonstrate significant differences in expression levels of 305 
Cd4 (n=4, P=0.018, sidebar=0-6), Cd8 (n=4, P=0.025, sidebar=0-5) and Foxp3 (n=4, P=0.034, 306 
sidebar=0-8) in co-injected muscles 14 days post-injection while Il-10 (n=6, P=0.124, 307 
sidebar=0.0-2.0) and Il-12 (n=4, P=0.132, sidebar=0.0-3.5) levels were not altered significantly.  308 
Figure 6 309 
Co-expression of IDO1 reduces antibody response against β-gal. The levels of anti-β-gal 310 
antibodies 14 days post-injection were significantly lower in sera from mice co-expressing the 311 
CMV-driven IDO1 plasmid (P=0.023, ANOVA with Tukey’s test). β-gal, n=7; β-gal+CD11c.mIDO1, 312 
n=5; β-gal+CMV.mIDO1, n=6. 313 
 314 
References 315 
 316 
1. Lavigne MD, Pohlschmidt M, Novo JF, Higgins B, Alakhov V, Lochmuller H, et al. 317 
Promoter dependence of plasmid-pluronics targeted alpha galactosidase A expression in 318 
skeletal muscle of Fabry mice. Mol Ther. 2005;12(5):985-90. 319 
2. Wells KE, Maule J, Kingston R, Foster K, McMahon J, Damien E, et al. Immune responses, 320 
not promoter inactivation, are responsible for decreased long-term expression following 321 
plasmid gene transfer into skeletal muscle. FEBS Lett. 1997;407(2):164-8. 322 
3. Marino M, Scuderi F, Provenzano C, Bartoccioni E. Skeletal muscle cells: from local 323 
inflammatory response to active immunity. Gene Ther. 2011;18(2):109-16. 324 
4. Blake DJ, Weir A, Newey SE, Davies KE. Function and genetics of dystrophin and 325 
dystrophin-related proteins in muscle. Physiol Rev. 2002;82(2):291-329. 326 
14 
 
5. Evans NP, Misyak SA, Robertson JL, Bassaganya-Riera J, Grange RW. Immune-mediated 327 
mechanisms potentially regulate the disease time-course of duchenne muscular dystrophy and 328 
provide targets for therapeutic intervention. PM R. 2009;1(8):755-68. 329 
6. Cirak S, Feng L, Anthony K, Arechavala-Gomeza V, Torelli S, Sewry C, et al. Restoration of 330 
the dystrophin-associated glycoprotein complex after exon skipping therapy in Duchenne 331 
muscular dystrophy. Mol Ther. 2012;20(2):462-7. 332 
7. Aoki Y, Yokota T, Wood MJ. Development of multiexon skipping antisense 333 
oligonucleotide therapy for Duchenne muscular dystrophy. Biomed Res Int. 2013;2013:402369. 334 
8. Malik V, Rodino-Klapac LR, Viollet L, Mendell JR. Aminoglycoside-induced mutation 335 
suppression (stop codon readthrough) as a therapeutic strategy for Duchenne muscular 336 
dystrophy. Ther Adv Neurol Disord. 2010;3(6):379-89. 337 
9. Goyenvalle A, Seto JT, Davies KE, Chamberlain J. Therapeutic approaches to muscular 338 
dystrophy. Hum Mol Genet. 2011;20(R1):R69-78. 339 
10. Mendell J, Campbell K, Rodino-Klapac L, Sahenk Z, Shilling C, Lewis S, et al. Transient 340 
Expression of a Therapeutic Dystrophin Transgene in Duchenne Muscular Dystrophy Revealed 341 
by T Cell Mediated Immunity. Neurology. 2010;74(9):A111-A. 342 
11. Dai Y, Schwarz EM, Gu D, Zhang WW, Sarvetnick N, Verma IM. Cellular and humoral 343 
immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and 344 
vector antigens allows for long-term expression. Proc Natl Acad Sci U S A. 1995;92(5):1401-5. 345 
12. Wang Z, Storb R, Halbert CL, Banks GB, Butts TM, Finn EE, et al. Successful regional 346 
delivery and long-term expression of a dystrophin gene in canine muscular dystrophy: a 347 
preclinical model for human therapies. Mol Ther. 2012;20(8):1501-7. 348 
13. Dobrzynski E, Fitzgerald JC, Cao O, Mingozzi F, Wang LX, Herzog RW. Prevention of 349 
cytotoxic T lymphocyte responses to factor IX-expressing hepatocytes by gene transfer-induced 350 
regulatory T cells. Proc Natl Acad Sci U S A. 2006;103(12):4592-7. 351 
14. Buhlmann JE, Foy TM, Aruffo A, Crassi KM, Ledbetter JA, Green WR, et al. In the absence 352 
of a CD40 signal, B cells are tolerogenic. Immunity. 1995;2(6):645-53. 353 
15 
 
15. Dobrzynski E, Herzog RW. Tolerance Induction by Viral In Vivo Gene Transfer. Clin Med 354 
Res. 2005;3(4):234-40. 355 
16. Ezzelarab M, Thomson AW. Tolerogenic dendritic cells and their role in transplantation. 356 
Semin Immunol. 2011;23(4):252-63. 357 
17. Mascarell L, Zimmer A, Van Overtvelt L, Tourdot S, Moingeon P. Induction of allergen-358 
specific tolerance via mucosal routes. Curr Top Microbiol Immunol. 2011;352:85-105. 359 
18. Gravano DM, Vignali DA. The battle against immunopathology: infectious tolerance 360 
mediated by regulatory T cells. Cell Mol Life Sci. 2012;69(12):1997-2008. 361 
19. Pallotta MT, Orabona C, Volpi C, Vacca C, Belladonna ML, Bianchi R, et al. Indoleamine 362 
2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells. Nat Immunol. 363 
2011;12(9):870-8. 364 
20. Madoiwa S, Yamauchi T, Hakamata Y, Kobayashi E, Arai M, Sugo T, et al. Induction of 365 
immune tolerance by neonatal intravenous injection of human factor VIII in murine hemophilia 366 
A. J Thromb Haemost. 2004;2(5):754-62. 367 
21. Zhang J, Xu L, Haskins ME, Parker Ponder K. Neonatal gene transfer with a retroviral 368 
vector results in tolerance to human factor IX in mice and dogs. Blood. 2004;103(1):143-51. 369 
22. Min B, Legge KL, Caprio JC, Li L, Gregg R, Zaghouani H. Differential control of neonatal 370 
tolerance by antigen dose versus extended exposure and adjuvant. Cell Immunol. 371 
2000;200(1):45-55. 372 
23. Ichino M, Mor G, Conover J, Weiss WR, Takeno M, Ishii KJ, et al. Factors Associated with 373 
the Development of Neonatal Tolerance After the Administration of a Plasmid DNA Vaccine. The 374 
Journal of Immunology. 1999;162(7):3814-8. 375 
24. Pilotte L, Larrieu P, Stroobant V, Colau D, Dolusic E, Frederick R, et al. Reversal of 376 
tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase. Proc Natl Acad Sci U S 377 
A. 2012;109(7):2497-502. 378 
16 
 
25. Hara M, Yokoyama H, Fukuyama K, Kitamura N, Shimokawa N, Maeda K, et al. 379 
Transcriptional regulation of the mouse CD11c promoter by AP-1 complex with JunD and Fra2 380 
in dendritic cells. Mol Immunol. 2013;53(3):295-301. 381 
26. Ni J, Nolte B, Arnold A, Fournier P, Schirrmacher V. Targeting anti-tumor DNA vaccines 382 
to dendritic cells via a short CD11c promoter sequence. Vaccine. 2009;27(40):5480-7. 383 
27. Edelmann SL, Nelson PJ, Brocker T. Comparative promoter analysis in vivo: 384 
identification of a dendritic cell-specific promoter module. Blood. 2011;118(11):e40-9. 385 
28. Young CN, Sinadinos A, Lefebvre A, Chan P, Arkle S, Vaudry D, et al. A novel mechanism 386 
of autophagic cell death in dystrophic muscle regulated by P2RX7 receptor large-pore formation 387 
and HSP90. Autophagy. 2015;11(1):113-30. 388 
29. Wolff J, Malone R, Williams P, Chong W, Acsadi G, Jani A, et al. Direct Gene Transfer into 389 
Mouse Muscle in Vivo. Science. 1990;247(4949 Pt 1):1465-8. 390 
30. Pan F, Yu H, Dang EV, Barbi J, Pan X, Grosso JF, et al. Eos mediates Foxp3-dependent 391 
gene silencing in CD4+ regulatory T cells. Science. 2009;325(5944):1142-6. 392 
31. Jung ID, Lee MG, Chang JH, Lee JS, Jeong YI, Lee CM, et al. Blockade of indoleamine 2,3-393 
dioxygenase protects mice against lipopolysaccharide-induced endotoxin shock. J Immunol. 394 
2009;182(5):3146-54. 395 
32. Gu T, Rowswell-Turner RB, Kilinc MO, Egilmez NK. Central role of IFNgamma-396 
indoleamine 2,3-dioxygenase axis in regulation of interleukin-12-mediated antitumor 397 
immunity. Cancer Res. 2010;70(1):129-38. 398 
33. Metghalchi S, Ponnuswamy P, Simon T, Haddad Y, Laurans L, Clement M, et al. 399 
Indoleamine 2,3-Dioxygenase Fine-Tunes Immune Homeostasis in Atherosclerosis and Colitis 400 
through Repression of Interleukin-10 Production. Cell Metab. 2015;22(3):460-71. 401 
34. Nitahara-Kasahara Y, Hayashita-Kinoh H, Chiyo T, Nishiyama A, Okada H, Takeda S, et al. 402 
Dystrophic mdx mice develop severe cardiac and respiratory dysfunction following genetic 403 
ablation of the anti-inflammatory cytokine IL-10. Hum Mol Genet. 2014;23(15):3990-4000. 404 
17 
 
35. Hedrich CM, Bream JH. Cell type-specific regulation of IL-10 expression in inflammation 405 
and disease. Immunol Res. 2010;47(1-3):185-206. 406 
36. Hsieh C, Macatonia S, Tripp C, Wolf S, O'Garra A, Murphy K. Development of TH1 CD4+ T 407 
cells through IL-12 produced by Listeria-induced macrophages. Science. 1993;260(5107):547-9. 408 
37. Eickhoff CS, Schnapp AR, Sagartz JE, Hoft DF. Lethal NK-mediated inflammation induced 409 
by IL-12 in the absence of polymorphic and nonpolymorphic MHC class I molecules. Cytokine. 410 
2013;64(1):25-9. 411 
38. Matino D, Gargaro M, Santagostino E, Di Minno MND, Castaman G, Morfini M, et al. IDO1 412 
suppresses inhibitor development in hemophilia A treated with factor VIII. The Journal of 413 
Clinical Investigation.125(10):3766-81. 414 
39. Shinde R, Shimoda M, Chaudhary K, Liu H, Mohamed E, Bradley J, et al. B Cell-Intrinsic 415 
IDO1 Regulates Humoral Immunity to T Cell-Independent Antigens. J Immunol. 416 
2015;195(5):2374-82. 417 
40. Vavrincova-Yaghi D, Deelman LE, van Goor H, Seelen MA, Vavrinec P, Kema IP, et al. 418 
Local gene therapy with indoleamine 2,3-dioxygenase protects against development of 419 
transplant vasculopathy in chronic kidney transplant dysfsunction. Gene Ther. 2016. 420 
41. Sinadinos A, Young CN, Al-Khalidi R, Teti A, Kalinski P, Mohamad S, et al. P2RX7 421 
Purinoceptor: A Therapeutic Target for Ameliorating the Symptoms of Duchenne Muscular 422 
Dystrophy. PLoS Med. 2015;12(10):e1001888. 423 
42. Lavigne MD, Yates L, Coxhead P, Gorecki DC. Nuclear-targeted chimeric vector 424 
enhancing nonviral gene transfer into skeletal muscle of Fabry mice in vivo. FASEB J. 425 
2008;22(6):2097-107. 426 
43. Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, et al. Fiji: an 427 
open-source platform for biological-image analysis. Nat Meth. 2012;9(7):676-82. 428 
44. Aubert D, Menoret S, Chiari E, Pichard V, Durand S, Tesson L, et al. Cytotoxic immune 429 
response blunts long-term transgene expression after efficient retroviral-mediated hepatic gene 430 
transfer in rat. Mol Ther. 2002;5(4):388-96. 431 






